Mylan Says 3rd Circ. Ruling Can't Boost EpiPen Antitrust Suit
By Khorri Atkinson · October 6, 2020, 6:48 PM EDT
Mylan told a Kansas federal judge on Monday that Sanofi is wrong to argue that a recent Third Circuit order, which also wiped out a $448 million AbbVie penalty over pay-for-delay claims, supports the French...
To view the full article, register now.